















While a drastic reduction in neonatal 
mortality has been observed over recent 
years, especially in developed countries, the 
incidence of prematurity has remained practi-
cally constant. Although various programs and 
therapeutic regimens have been implemented 
to reduce the incidence of premature birth, 
the rate remains between 5% and 18%.1 
These premature births account for 80% of 
all neonatal deaths.1 In the city of Campinas, 
State of Sao Paulo, Brazil, a survey indicated 
that 9.5% of newborns had low birth weight 
and 6.2% were premature.2 
The multiple risk factors associated with 
prematurity include premature rupture of the 
membranes, previous premature birth, heavy 
physical work, black ethnicity and age greater 
than 30 years old.3,4 To prevent prematurity, the 
ideal course of action would be to predict which 
patients are at risk of premature delivery and 
then implement effective intervention.5-7
In several studies, bacterial vaginosis 
has been associated with prematurity and 
other adverse outcomes, independent of other 
known risk factors.8-12 While bacterial vagino-
sis has been associated with preterm delivery 
and low birth weight, randomized trials for 
the treatment of bacterial vaginosis during 
pregnancy have not always demonstrated a 
reduction in such outcomes.11,13
The treatment of choice for bacterial vagi-
nosis has been metronidazole in the United 
States.14 Trials have found a signifi cant reduc-
tion in the rate of premature births among 
pregnant women who presented high risk of 
prematurity and whose bacterial vaginosis was 
treated with metronidazole.15,16 On the other 
hand, there are similar trials that did not fi nd 
a decrease in the prematurity rates among low-
risk populations.13,17,18 The lack of benefi cial 
effect from metronidazole may, however, be 
related to the dosing regimens used.18 
A recent meta-analysis that compared 
treatment of bacterial vaginosis with placebo 
found that the evidence did not support sys-
tematic screening for and treatment of bacte-
rial vaginosis for all pregnant women, aimed 
at preventing premature birth, postpartum 
infection and neonatal sepsis.11 However, there 
was evidence that indicated that, for women 
with a history of premature birth, treatment 
of bacterial vaginosis could prevent subsequent 
preterm birth.11
A Brazilian study has found 20% preva-
lence of bacterial vaginosis among asymp-
tomatic pregnant women.12,19 In addition, a 
signifi cantly increased risk of neonatal com-
plications was found among this population.12 
The present study was conducted to evaluate 
the impact of treatment for bacterial vaginosis 
among a population of Brazilian pregnant 
women, in order to prevent prematurity and 
other undesired outcomes from pregnancy.
METHODS
In an attempt to determine whether the 
treatment of bacterial vaginosis during prenatal 
care reduced the incidence of preterm delivery, 
we conducted the present observational retro-
spective cohort study among all 785 women 
who were attending the Obstetric Service at the 
Universidade Estadual de Campinas (Unicamp), 
Brazil, between January 1997 and March 1999. 
The study made use of the results from vaginal 
Gram stains available in the patients’ records. 
The women were categorized in three different 
groups that were identifi ed with regard to bacterial 
vaginosis: one group without detection of bacte-
rial vaginosis at the fi rst prenatal care visit (580 
women); one group with bacterial vaginosis treat-
ed with imidazolic antibiotics during pregnancy 
(134 women); and one group with bacterial 
vaginosis that was not treated during the gestation 
(71 women). Institutional Review Board approval 
was obtained for the study. 
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CONTEXT AND OBJECTIVE: Bacterial vaginosis 
has been associated with prematurity and other 
perinatal complications. However, the effi cacy 
of the treatment for preventing such complica-
tions has not yet been well established. The 
objective of this study was to evaluate the 
impact of treatment for bacterial vaginosis on 
a low-risk population of Brazilian pregnant 
women, in order to prevent prematurity and 
other perinatal complications.
DESIGN AND SETTING: Observational retrospec-
tive cohort study, at the Obstetric and Gynecol-
ogy Department, Universidade Estadual de 
Campinas (Unicamp).
METHODS: Vaginal bacterioscopy results from 
785 low-risk pregnant women were studied. 
Three different groups of women were identi-
fi ed: 580 without bacterial vaginosis during 
pregnancy, 134 with bacterial vaginosis treated 
using imidazoles (metronidazole, tinidazole, or 
secnidazole) during pregnancy, and 71 with bac-
terial vaginosis not treated during pregnancy. The 
diagnosis of bacterial vaginosis was based on 
Nugent’s criteria, from the vaginal bacterioscopy 
performed during the fi rst prenatal care visit.
RESULTS: The frequency of prematurity was 5.5% 
among the women without bacterial vaginosis, 
22.5% among those with untreated bacterial 
vaginosis and 3.7% among those with treated 
bacterial vaginosis. The risk ratios for perinatal 
complications were signifi cantly higher in the 
group with untreated bacterial vaginosis: pre-
mature rupture of membranes, 7.5 (95% CI: 
1.9-34.9); preterm labor, 3.4 (95% CI: 1.4-8.1); 
preterm birth, 6.0 (95% CI: 1.9-19.7); and low 
birth weight, 4.2 (95% CI: 1.2-14.3). 
CONCLUSION: The treatment of bacterial vagino-
sis signifi cantly reduced the rates of prematurity 
and other perinatal complications among these 
low-risk Brazilian pregnant women, regardless of 
the history of previous preterm delivery.
KEY WORDS: Bacterial vaginosis. Pregnancy. 
Premature infant. Perinatal care. Pregnancy 
complications.
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The diagnosis of bacterial vaginosis was 
based on Gram’s stain, using Nugent’s crite-
ria.20 Vaginal swab samples had been collected 
from each pregnant woman during the first 
prenatal care visit. The decision regarding 
which antiprotozoal agent to use (metroni-
dazole, tinidazole or secnidazole) was based 
on the attending physicians’ choice and the 
availability of the agents at the clinic.
Women were not included in this study 
if they had: gestational age greater than 34 
weeks at the first prenatal care visit, diabetes, 
arterial hypertension of any etiology, multiple 
gestations, polyhydramnios, placenta previa, 
abruptio placentae, fetal malformation, or 
infection of the genital tract by Trichomonas 
vaginalis, Chlamydia trachomatis or Neisseria 
gonorrhoeae. All these exclusion criteria were 
based on the appearance of such diagnoses in 
the patient’s chart.
Tinidazole and secnidazole have been ap-
proved for use in Brazil, and also in Europe, 
and are comparable to metronidazole with 
regard to efficacy. Tinidazole and secnidazole 
are frequently used as an alternative to metro-
nidazole, depending on their availability in the 
hospital pharmacy, and they are dispensed to 
patients at Unicamp without charge. 
As there are essentially no known differ-
ences in the treatment regimens with regard 
to their efficacy for treating bacterial vagi-
nosis at the time of the study, we found that 
several therapeutic regimens had been used: 
metronidazole, 750 mg/day, orally for seven 
days (57 women); metronidazole, tinidazole 
or secnidazole, 2 g orally, single dose (three, 
four and four women, respectively); or met-
ronidazole or 0.75% tinidazole gel, one full 
applicator, intravaginally once a day for seven 
days (36 and nine women respectively). The 
imidazole administration route was not stated 
in the clinical record files for 21 patients with 
treated bacterial vaginosis.
The therapeutic regimen was chosen at the 
discretion of the attending clinician. They had 
greatly differing opinions regarding treatment. 
Since, at that time, treatment was not consid-
ered to be mandatory, several attending physi-
cians did not treat cases of bacterial vaginosis. 
Furthermore, some women’s clinical records 
confirmed that bacterial vaginosis had been 
treated using one of these drugs, but the imid-
azole administration route was not stated.
Preterm-premature rupture of membranes 
was defined as rupture of the amniotic mem-
branes before the 37th week of pregnancy and 
before the onset of labor.
Premature labor was defined as the oc-
currence of regular and persistent uterine 
contractions before the 37th week of pregnancy. 
In addition, the patient had to demonstrate 
cervical dilatation and effacement that re-
quired treatment using tocolytics.
A premature birth was defined as a new-
born with less than 37 weeks (259 days) of ges-
tation. The length of gestation was determined 
from the date of the last menstrual period, 
obstetric sonography, and/or examination of 
the newborn using the Capurro method.21
Newborns weighing less than 2,500 g were 
considered to have low birth weight.
Infants were considered to present neo-
natal morbidity if they developed complica-
tions during the newborn period requiring 
admission to the neonatal semi-intensive 
and/or intensive care unit (for example, due 
to respiratory distress, neonatal anoxia, hypo-
glycemia, or sepsis).
Maternal morbidity was considered to be 
present if there was the presence of endometri-
tis and/or infection of a surgical wound that 
required hospital admission.
Chorioamnionitis was defined as maternal 
fever (temperature ≥ 38° C) and amniotic 
fluid with odor. 
The statistical analysis was performed us-
ing the chi-squared and Fisher exact tests for 
category variables, and variance analysis for 
quantitative variables. For the main dependent 
variables, the risk ratio was calculated with a 
95% confidence interval. Furthermore, multi-
ple logistical regression analysis was performed 
to compare the groups with treated bacterial 
vaginosis and untreated bacterial vaginosis. 
RESULTS
The average ages in years were 26.6 (± 6.9), 
24.8 (± 6.9) and 24.3 (± 6.1), respectively, for 
the groups without bacterial vaginosis, with 
treated bacterial vaginosis and with untreated 
bacterial vaginosis. Eighty-two percent of the 
samples (647/785) were collected before 30 
weeks of gestation, and the mean gestational 
age at the time of collection was 23.5 weeks. 
There were no statistically significant differ-
ences between the three groups with regard 
to the sociodemographic characteristics, 
habits and obstetric antecedents, except for 
the smoking habit, which was higher in the 
groups with bacterial vaginosis. 
There were no significant differences 
in preterm-premature rupture of amniotic 
membranes, premature labor, premature birth 
and low-birth-weight newborns between the 
group without bacterial vaginosis and the 
treated group. On the other hand, there was a 
statistically significant difference between the 
groups with treated and untreated bacterial 
vaginosis, with regard to adverse perinatal 
outcomes (Table 1).
The multiple logistical regression analysis 
for the treated and untreated bacterial vagi-
nosis groups identified younger age and un-
treated bacterial vaginosis as factors that were 
associated with preterm-premature rupture of 
amniotic membranes. The factors associated 
with premature labor were preterm-premature 
rupture of amniotic membranes and untreated 
bacterial vaginosis, while the factors associated 
with premature birth were preterm-premature 
rupture of amniotic membranes, preterm labor 
and untreated bacterial vaginosis. Finally, the 
regression model only identified premature 
birth as a statistically significant factor associ-
ated with low birth weight.
There was no occurrence of puerperal 
infection or amnionitis in the group with 
treated bacterial vaginosis and low frequency 
of this in the group without bacterial vagi-
Table 1. Comparison of adverse perinatal outcomes between pregnant women groups 
with treated and untreated bacterial vaginosis in a university hospital in Brazil
Adverse perinatal outcomes Treated bacterial  
vaginosis 
Untreated bacterial  
vaginosis
p-value
n % n %
Preterm-premature rupture 
of amniotic membranes 3/134 2.2 12/71  16.9 < 0.001
*
Premature labor 11/134 8.2 20/71  28.2 < 0.001†
Premature birth 5/134 3.7 16/71  22.5 < 0.001‡
Low birth weight 5/134 3.7 11/71  15.5 0.003§
Puerperal infection - - 4/71  5.6 0.013
Amnionitis - - 2/71  2.8 0.045
Length of stay in neonatal 
intensive care unit 
≥ 2 days
1/134 0.7 4/71  5.6 0.049
Neonatal morbidity 9/134 6.7 13/71  18.3 0.020
Risk Ratio (95% CI): *7.55  (1.90 - 34.93); †3.43 (1.46 - 8.15); ‡6.04 (1.97 - 19.76); §4.15 (1.27 - 14.35).
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nosis. Conversely, the occurrence of puer-
peral infection, amnionitis and neonatal 
morbidity, and the length of stay in neonatal 
intensive care units, was significantly higher 
in the group with untreated bacterial vagi-
nosis than in the group with treated bacterial 
vaginosis (Table 1). 
An analysis of the subgroups, excluding 
women with a history of previous preterm 
delivery, was also performed. No significant 
differences in the incidence of perinatal 
complications was found between the groups 
without bacterial vaginosis and with treated 
bacterial vaginosis, except with respect to 
preterm-premature rupture of amniotic mem-
branes (0.2% versus 2.5%; p = 0.026). 
On the other hand the incidence of most 
perinatal complications was significantly 
higher in the group with untreated bacterial 
vaginosis than in the group with treated bacte-
rial vaginosis (Table 2). 
The relationship between the incidence 
of perinatal complications and the different 
routes of treatment (oral or vaginal) was also 
analyzed. No significant differences were 
found with regard to preterm-premature rup-
ture of membranes, premature labor and low 
birth weight in the groups with oral or vaginal 
treatment. Premature birth was significantly 
more frequent in the subgroup with vaginal 
treatment (p = 0.008).
DISCUSSION
The results of this study have demonstrat-
ed that the treatment of bacterial vaginosis had 
a favorable impact on reducing the occurrence 
of preterm-premature rupture of amniotic 
membranes, premature labor and birth, low 
birth weight, and neonatal morbidity among 
Brazilian women. These complications were 
significantly less frequent among the preg-
nant women with treated bacterial vaginosis 
than among those with untreated bacterial 
vaginosis. Furthermore, the frequencies were 
similar between the women with treated bacte-
rial vaginosis and the controls (those without 
bacterial vaginosis).
The three groups of women were homo-
geneous with regard to obstetric and sociode-
mographic characteristics. In general, these 
variables had homogeneous distribution in 
the sample, except for smoking. Even so, when 
smoking was compared only between the two 
groups with bacterial vaginosis (treated and 
untreated), the difference was not significant 
for this variable, either. Since these two groups 
did not differ in demographic characteristics, 
we can assume that these demographic char-
acteristics had no impact or association with 
preterm birth in this study. 
The women were not randomized and 
there were no criteria used in making the 
decision of whether to treat (and which route 
to use for the imidazole) or not to treat. The 
attending physician had the responsibility for 
making these decisions, and this may have 
introduced a significant selection bias.
Preterm labor was the most prevalent neo-
natal outcome for all groups. The occurrence 
of preterm labor was three times higher in the 
group with untreated bacterial vaginosis than 
among the treated women. Preterm-premature 
rupture of amniotic membranes occurred 
seven times more frequently in the group 
with untreated bacterial vaginosis than in the 
group with treated bacterial vaginosis. A recent 
publication has also demonstrated that treat-
ment of bacterial vaginosis during the prenatal 
period resulted in a reduction in the rate of 
premature rupture of the membranes, but only 
for women at higher risk of prematurity, i.e. 
those with a history of preterm birth.11 This 
Table 2. Comparison of adverse perinatal outcomes between the pregnant women 
groups with treated and untreated bacterial vaginosis, excluding the women with  
a history of preterm delivery* in a university hospital in Brazil
Adverse perinatal outcomes Treated bacterial 
vaginosis 
Untreated bacterial  
vaginosis
p-value
n % n %
Preterm-premature rupture 
of amniotic membranes 3/120  2.5 12/66  18.2 < 0.001
Premature labor 10/120  8.3 17/66  25.7 0.002
Premature birth 5/120  4.2 14/66  21.2 < 0.001
Low birth weight 5/120  4.2 9/66  13.6 0.037
Puerperal infection - - 4/66  6.1 0.015
Amnionitis - - 1/66  1.5 0.215
Neonatal morbidity 4/120  3.3 5/66  7.6 0.284
*Fourteen women had previous preterm delivery among the women with treated bacterial vaginosis and five in the untreated 
bacterial vaginosis group.
suggests that women at risk of preterm delivery 
should be screened, if possible prior to concep-
tion or early in the pregnancy, and treated. 
Women with a history of preterm delivery 
and bacterial vaginosis may have subclinical 
or asymptomatic endometritis and therefore 
may experience an inflammatory response 
when becoming pregnant. Developing recur-
rent episodes of bacterial vaginosis may induce 
an enhanced inflammatory response, thereby 
resulting in premature rupture of amniotic 
membranes and preterm labor, or preterm 
labor with intact amniotic membranes. Korn 
et al.22 showed the existence of asymptomatic 
endometritis in non-pregnant women. 
The estimated risk of preterm birth was 
six times higher among women with untreated 
bacterial vaginosis than in the group with 
treated bacterial vaginosis. The high rate of 
preterm birth among women with untreated 
bacterial vaginosis is perhaps explained, in 
part, by the design limitations of the study. 
The relative risk of preterm birth among 
women with bacterial vaginosis ranges from 
1.5 to 3.0 in most of the published stud-
ies.8,9,23,24 These rates are rather lower than the 
rate found in the present study. However, Hay 
et al.25 also found a relative risk of 7.3, which 
is very similar to our results. In addition, other 
published data have also suggested that treat-
ment of bacterial vaginosis during pregnancy 
can reduce the risk of neonatal complications, 
especially prematurity.3,16,22
The incidence of low-birth-weight infants 
was four times higher in the group of women 
with untreated bacterial vaginosis than among 
those with treated bacterial vaginosis. Low 
birth weight has been assumed to be a result 
of the preterm-premature rupture of amniotic 
membranes and the preterm birth, rather than 
a direct complication of bacterial vaginosis.
Puerperal infection was a significant 
outcome in this study in the group with 
untreated bacterial vaginosis. In all cases 
of puerperal infection, the delivery was by 
means of cesarean section. It is important to 
highlight that all the women who underwent 
cesarean section received cephazolin 1 g, IV 
in a single dose, immediately after cutting 
the umbilical cord, as a routine prophylactic 
procedure of our service. It seems that this 
antibiotic prophylaxis is not as effective as 
expected in preventing puerperal infection 
among women with bacterial vaginosis at 
the time of delivery. In the literature, there 
is also evidence that bacterial vaginosis can 
be an important risk factor for endometritis 
after cesarean deliveries, in spite of antibiotic 
prophylaxis using cephalosporin.26 
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Comparing the oral and intravaginal 
treatment regimens, prematurity occurred 
more frequently among women treated with 
intravaginal antibiotic. There was a limita-
tion on this evaluation, because 21 patients 
with treated bacterial vaginosis had no data 
available on their charts to show the route of 
imidazole administration. Also, the patients 
who were treated with antibiotics received one 
of six possible regimens. Such variance in treat-
ment makes it difficult to draw conclusions 
about what actual effect there was. Neverthe-
less, this result is in agreement with a recent 
meta-analysis demonstrating that systemic 
treatment during pregnancy was more effica-
cious than intravaginal metronidazole.11
On the other hand, Carey et al.13 did not 
find a reduction in the rates of prematurity or 
other neonatal complications. However, they 
used 2 g of metronidazole twice for treatment 
of bacterial vaginosis. Treatment of bacterial 
vaginosis with a single dose of metronidazole 
is associated with higher rates of relapse than is 
treatment over a long period of time, especially 
when long-term cure rates are analyzed.14 
Admission of the newborn to the neo-
natal intensive care unit was significantly 
more frequent for the group of women with 
untreated bacterial vaginosis. A reduction 
in neonatal intensive care unit admissions 
can significantly reduce costs. Müller et al.27 
recently demonstrated the cost benefit of 
diagnosis and treatment of bacterial vaginosis 
during pregnancy for reducing admissions to 
the neonatal intensive care unit in Germany. 
This can have an even greater importance in 
developing countries.
However, the issue of screening for and 
treating bacterial vaginosis among pregnant 
women remains unsettled. The current litera-
ture suggests that only women with a history 
of preterm birth can benefit from treatment of 
bacterial vaginosis.11 In the present study, an 
analysis of women not at risk of preterm birth 
(i.e. with no history of previous prematurity) 
found that these women also benefited from 
treatment for bacterial vaginosis. 
CONCLUSION
This study shows that treating bacterial 
vaginosis during pregnancy could significantly 
reduce the risk of prematurity among Bra-
zilian pregnant women. Treating bacterial 
vaginosis in these pregnant women resulted in 
a significant reduction in premature rupture 
of the membranes, preterm birth, postpar-
tum endometritis, and neonatal sepsis. This 
positive effect was also demonstrated among 
pregnant women without a history of prema-
ture birth. However, because the currently 
available knowledge is still controversial, and 
this study had some limitations, similar stud-
ies are needed in distinct populations, before 
universal screening and treatment of bacterial 
vaginosis among pregnant women in develop-
ing countries can be recommended.
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RESUMO
Impacto do tratamento da vaginose bacteriana sobre a prematuridade em grávidas Brasileiras:  
um estudo tipo coorte retrospectivo
CONTEXTO E OBJETIVO: A vaginose bacteriana vem sendo apontada como fator de risco para prema-
turidade e outras complicações perinatais. Entretanto, a eficácia do seu tratamento na prevenção destas 
complicações ainda não está esclarecida. O objetivo deste estudo foi avaliar o impacto do tratamento 
da vaginose bacteriana durante o pré-natal de baixo risco para a prevenção de prematuridade e outras 
complicações perinatais.
TIPO DE ESTUDO E LOCAL: Coorte retrospectivo observacional, no Departamento de Tocoginecologia, 
Universidade Estadual de Campinas (Unicamp).
MÉTODOS: Foram estudadas 785 gestantes de baixo risco com resultado da bacterioscopia de secreção 
vaginal. Foram identificados três grupos de mulheres: 580 sem vaginose bacteriana durante a gestação, 
134 com vaginose bacteriana tratada com imidazólicos (metronidazol, tinidazol, ou secnidazol) durante a 
gestação, e 71 com vaginose bacteriana não tratada durante a gestação. O diagnóstico de vaginose bac-
teriana foi realizado utilizando os critérios de Nugent na bacterioscopia vaginal da primeira consulta. 
RESULTADOS: O parto prematuro ocorreu em 5,5% do grupo de mulheres sem vaginose bacteriana, 22,5% 
do grupo com vaginose bacteriana não tratada, e 3,7% do grupo com vaginose bacteriana tratada. A 
razão de risco para as complicações perinatais no grupo com vaginose bacteriana não tratada durante 
a gestação foi: 7,5 (intervalo de confiança, IC, de 95%: 1,9-34,9) para rotura prematura de membranas 
no pré-termo, 3,4 (IC de 95%: 1,4-8,1) para trabalho de parto prematuro, 6,0 (IC de 95%: 1,9-19,7) 
para parto prematuro e 4,2 (IC de 95%: 1,2-14,3) para baixo peso ao nascer. 
CONCLUSÃO: O tratamento da vaginose bacteriana reduziu significativamente os índices de prematuri-
dade e outras complicações perinatais entre as gestantes de baixo risco, independentemente da história 
prévia de parto prematuro.
PALAVRAS CHAVE: Vaginose bacteriana. Gravidez. Prematuro. Assistência perinatal. Complicações 
na gravidez.
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